Abstract:Introduction: The complexity of Inflammatory Bowel Diseases (IBD) presents challenges for the management of these diseases. Predicting treatment outcomes remains difficult, leading to suboptimal outcomes and high costs. Emerging evidence suggests the potential of the gut microbiome in predicting response to biologic treatments. In this prospective study we aimed to predict treatment response to vedolizumab and ustekinumab in 79 IBD patients by integrating clinical data, gut microbiome profiles and fecal metabolites and validating these findings in a replication cohort of 47 IBD patients. Methods: Treatment response was defined as either continuation or discontinuation of the biologic at six months. We performed whole genome metagenomic shotgun sequencing on the baseline fecal samples to detect microbial and functional profiles. Additionally, over 1000 metabolites were captured through untargeted metabolomic profiling. Baseline diversity, dissimilarity and differential abundance analyses compared responder and non-responder groups. The prediction tool CoDaCoRe was used to identify predictive log-ratio biomarkers. We tested our identified ratios in an external cohort and attempted to replicate the microbiome-based signals of previous studies. Finally, we used a neural-network framework to model the relationship between metabolites and microbes, comparing these clusters in responders and non-responders and tested our approach with different definitions of response. Results: We identified seven metabolites to be differentially abundant between responders and non-responders (FDR < 0.05). However, no significant differences in bacterial species and pathways were detected at baseline between responders and non-responders. Our prediction analysis indicated only marginal predictive utility of the gut microbiome and fecal metabolites for treatment response, when compared to a clinical model using fecal calprotectin, disease duration and disease activity, among other factors (AUC only clinical features: 0.71±0.13, AUC microbial and clinical features: 0.73±0.12). The main predictive features of these models were the disease activity and previous anti-TNF use combined with high abundance of Phocaeicola vulgatus, Bacteroides uniformis and Alistipes onderdonkii, and the low abundance of Ruminococcus gnavus and Faecalibacterium prausnitzii. Testing our identified ratio of 10 species in an external cohort of 47 IBD patients reinforced the lack of predictive power of the microbiome. No replication of previously published predictive signals of the microbiome was observed. Additionally, we identified 2 metabolite clusters and 1 microbiome cluster associated with response, and observed that predictors were highly dependent on the definition of response. Conclusion: While previous studies of similar size have shown that microbial features can predict response to either vedolizumab (VedoNet), or vedolizumab, ustekinumab and anti-TNF, our comprehensive study found no significant differences in the gut microbiome at baseline between responders and non-responders among IBD patients treated with ustekinumab or vedolizumab. Microbial features added no predictive power to drug response in our IBD patient cohort or an independent replication cohort. Addition of metabolite features did not improve predictive power. These findings suggest minimal impact of the pre-treatment gut microbiome on treatment outcomes with these medications in IBD patients with long term chronic disease. Generalizability beyond initial study cohorts is limited, leaving predictors for individualized IBD-medication selection unidentified, but based on this work, likely do not lie in the fecal microbiome.

P181 Combination of EPIC-CD epigenetic signatures accurately identifies non-response to multiple biologics in patients with active Crohn’s disease

P592 Higher predictive power of epigenetic signatures for response to vedolizumab and ustekinumab in anti-TNF naïve patients with active Crohn’s disease

Peripheral blood DNA methylation signatures predict response to vedolizumab and ustekinumab in adult patients with Crohn's disease: The EPIC-CD study

OP03 Highly stable epigenome-wide peripheral blood DNA methylation signatures accurately predict endoscopic response to adalimumab, vedolizumab and ustekinumab in Crohn’s disease patients: The EPIC-CD study

P1042 Serum N-glycan Biomarkers Predict Patient Response to Biologics for Crohn’s Disease

P509 Biomarkers of neutrophil activity and extracellular matrix turnover predict long-term response to vedolizumab in patients with Crohn’s disease

P695 Untargeted proteomics analysis of baseline serum samples prior to biologic therapy initiation

P1195 Identification of immune cell infiltration and potential candidate biomarker in anti-IL 12/23 treated Crohn’s disease patients by integrated bioinformatics analysis and machine learning

P915 Multi-Omics Biomarkers for the Prediction of Response to Biologics in Patients with Inflammatory Bowel Disease

Single-cell characterization of peripheral blood mononuclear cells from vedolizumab-treated patients with Crohn's disease identifies response-associated differences among the plasmacytoid dendritic cell and classical monocyte populations.

P206 Metabolomic predictors of response to vedolizumab in Inflammatory Bowel Disease

OP05 High-dimensional single-cell analysis identifies cellular signatures associated with response to vedolizumab therapy in ulcerative colitis

DOP22 Predictive biomarkers of therapeutic response in Inflammatory Bowel Disease: a step towards personalized medicine

P665 Which second-line biologic after anti-TNF failure during Crohn’s disease: Ustekinumab or vedolizumab, a multicentre retrospective study

Limited predictive value of the gut microbiome and metabolome for response to biological therapy in inflammatory bowel disease

Delayed Ustekinumab and Adalimumab Responders Have Similar Outcomes as Early Responders in Biologic-Naïve Crohn's Disease

Intestinal mRNA expression profiles associated with mucosal healing in ustekinumab-treated Crohn's disease patients: bioinformatics analysis and prospective cohort validation

P1026 Clinical decision support tool for vedolizumab could not predict outcome in ulcerative colitis patients – a retrospective real-life single-centre cohort study

P699 Ustekinumab therapy after biologic failure in patients with Crohn’s Disease – A real-world single centre experience

P803 iGenoMed-MTT: A prospective multiomic study of response to molecularly targeted therapies in IBD

Crohn’s Patient Serum Proteomics Reveals Response Signature for Infliximab but not Vedolizumab